Results 141 to 150 of about 1,663 (174)

Switching to Ziv-aflibercept In Resistant Diabetic Macular Edema Non Responsive to Ranibizumab Injection

, 2021
Amin E. Nawar, Tamer Wasfy, Heba M. Shafik   +2 more
openalex   +1 more source

A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas. [PDF]

Oncologist, 2018
Meehan R, Kummar S, Do K, O'Sullivan Coyne G, Juwara L, Zlott J, Rubinstein L, Doroshow JH, Chen AP.   +8 more
europepmc   +1 more source

Three‐month outcomes of ziv‐aflibercept in the treatment of diabetic macular oedema [PDF]

Acta Ophthalmologica, 2016
Mohammed, Ashraf, Ahmed A R, Souka, Hassan, El Kayal, Mostafa, El Manhaly, Mohamed Hossam, Abdallah   +4 more
openaire   +2 more sources

Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion

Indian Journal of Ophthalmology, 2015
Jay Chhablani
doaj   +1 more source

Ziv‐aflibercept: A cost‐effective, off‐label, highly potent antagonist of vascular endothelial growth factor [PDF]

, 2019
Ahmad M. Mansour, Michael W. Stewart, Michel Eid Farah, Hana A. Mansour, Jay Chhablani   +4 more
openalex   +1 more source

Comparison of Safety and Efficacy of Intravitreal Ziv-Aflibercept Vs Bevacizumab for the Treatment of Macular Edema

, 2020
Hussain Ahmad Khaqan, Usman Imtiaz, Hasnain Muhammad Buksh, Hafiz Ateeq Ur Rehman, Raheela Naz   +4 more
openalex   +1 more source

Ziv-aflibercept Efficacy in Better Regulating Neovascular AMD (ZEBRA) Trial

, 2019
Haley S. D’Souza, Kapil Kapoor, Alan L. Wagner   +2 more
openalex   +1 more source

Clinical Outcomes of High-Dose Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Bousamri A, Al-Shehri M, Mestarihi M, Almutairi TB, Alaredhi M, Mahanna B, Alharbi F.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Intravitreal Ziv-Aflibercept: A Comprehensive Review

Seminars in Ophthalmology, 2019
Background: Age-related macular degeneration is the leading cause of blindness in adults over the age of 50 in the United States of America. Neovascular age-related macular degeneration (nAMD) is sight-threatening, but can be treated by three currently utilized, intravitreally administered drugs: aflibercept, bevacizumab, and ranibizumab.
Haley S D'souza, Daniel Barmas-Alamdari
exaly   +3 more sources